SCHEMBL7147873

SCHEMBL7147873

Nc1nc(SCCc2ccccn2)cc(-c2ccco2)n1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 0.57
ADORA1 P30542 14/20 0.57
ADORA3 P0DMS8 9/20 0.57
ADORA2B P29275 8/20 0.57
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
ALOX12 P18054 1/20 0.46
RECQL P46063 1/20 0.46
HBB P68871 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151390 0.84 ADORA2A (0.55) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7146951 0.78 ADORA2A (0.55) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7149434 0.77 ADORA2A (0.45) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7151993 0.76 KDM4E (0.57) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7146168 0.76 ALDH1A1 (0.60) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5039866 0.76 ADORA2A (0.48) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5037036 0.76 ADORA2A (0.48) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5044504 0.76 ADORA2A (0.48) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL7144880 0.74 ADORA2A (0.47) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL931112 0.73 ADORA2A (0.81) ADORA2AADORA1ADORA3ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.